Cancer Treatment Reviews
Volume 31 , Pages S3-S9 , 2005

How to maximize the efficacy of taxanes in breast cancer

References 

  1. Rahman ZU, Frye DK, Smith TL, et al. Results and long-term follow up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy. A reference. Cancer. 1999;85(1):104–111
  2. Fossati R, Confalonieri C, Torri V, et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomised trials involving 31,510 women. J Clin Oncol. 1998;16:3439–3460
  3. Ghersi D, Wilcken N, Simes J, Donoghue E. Taxane containing regimens for metastatic breast cancer (Cochrane Review). The Cochrane Library, Issue 2. 2005. Chichester UK: John Wiley and Sons Ltd; 2005;
  4. Gralow J. Optimising the treatment of metastatic breast cancer. Breast Cancer Res Treat. 2005;89(Suppl 1):S9–S15
  5. Jones S, Erban J, Overmoyer B, et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol. 2005;23(24):5542–5551
  6. Bontembal M, Braun JJ, Creemers GJ, et al. Phase III study comparing AT to FAC as first-line chemotherapyin patients with metastatic breast cancer. EJC Supplements. 2003;S201
  7. Abstract 88 Luck HJ, Thomssen C, Untch M, et al. multicentric phase III study in firstline treatment of advanced metastatic breast cancer Epirubicin/paclitaxel vs Epirubicin/cyclophosphamide. ASCO; 2000;
  8. Biganzoli L, Cufer T, Bruning P, Coleman R, Duchateau L, Calvert AH, et al. Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial. J Clin Oncol. 2002;20(14):3114–3121
  9. Sledge GW, Neuberg D, Bernardo P, Ingle JN, Martino S, Rowinsky EK, et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol. 2003;21(4):588–592
  10. Nabholtz JM, Falkson G, Campos D, et al. Docetaxel and doxorubicin (AT) compared to doxorubicin and cyclophosphamide (AC) as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol. 2003;21:968–975
  11. Spielmann M, Tubiana-Hulin M, Namer M, Mansouri H, Bougnoux P, Tubiana-Mathieu N, et al. Sequential or alternating administration of docetaxel (Taxotere) combined with FEC in metastatic breast cancer: a randomised phase II trial. Br J Cancer. 2002;86(5):692–697
  12. Bonneterre J, Dieras V, Tubiana-Hulin M, et al. Phase II multicentre randomised study of docetaxel plus epirubicin vs. 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer. Br J Cancer. 2004;91:1466–1471
  13. Reyes S et al. ECCO 2003 (Abstract 447).
  14. Perez EA. Carboplatin in combination therapy for metastatic breast cancer. Oncologist. 2004;9(5):518–527
  15. Fountzilas G, Kalofonos HP, Dafni U, et al. Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol. 2004;15(10):1517–1526
  16. O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol. 2002;20(12):2812–2823
  17. (July 15 Suppl) Albain KS, Nag S, Calderillo-Ruiz G, et al. Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): first report of overall survival. J Clin Oncol 2004. ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2004;22(14S):510
  18. Colomer R. What is the best schedule for administration of gemcitabine-taxane?. Cancer Treatment Rev. 2005;31(Suppl 4):23–28
  19. Baselga J, Tabernero JM. Weekly docetaxel in breast cancer. Applying clinical data to patient therapy. Oncologist. 2001;6(Suppl. 3):26–29
  20. Burstein HJ, Manola J, Younger J, et al. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol. 2000;18(6):1212–1219
  21. Salmon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–792
  22. Marty M, Cognetti F, Maraninchi D, et al. Efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: results of a randomized phase II trial by the M77001 study group. J Clin Oncol. 2005;

PII: S0305-7372(05)80002-7

Cancer Treatment Reviews
Volume 31 , Pages S3-S9 , 2005

Article Tools